B of A Securities Upgrades Day One Biopharmaceutical to Buy, Raises Price Target to $24
B of A Securities Upgrades Day One Biopharmaceutical to Buy, Raises Price Target to $24
美銀證券將第一生物製藥評級升級爲買入，將價格目標提高至24美元。
B of A Securities analyst Alec Stranahan upgrades Day One Biopharmaceutical (NASDAQ:DAWN) from Underperform to Buy and raises the price target from $11 to $24.
B of A證券分析師Alec Stranahan將Day One生物製藥（NASDAQ：DAWN）從弱勢股票升級爲買入，並將價格目標從11美元上調至24美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。